- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urgency-frequency Syndrome
- Interventions
- InterStim Basic Evaluation lead and foramen needle
- Device
- Lead sponsor
- MedtronicNeuro
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 10
- States / cities
- St. Petersburg, Florida • Tampa, Florida • Plymouth, Minnesota + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1105–1128
of 1,585
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Over-Active Bladder
- Interventions
- Solifenacin succinate, Placebo
- Drug
- Lead sponsor
- Advanced Research Network
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Interventions
- eCoin Tibial Nerve Stimulation
- Device
- Lead sponsor
- Valencia Technologies Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 15
- States / cities
- Downey, California • Redwood City, California • San Diego, California + 12 more
- Conditions
- Cancer
- Interventions
- management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
- Procedure
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Urinary Bladder, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- UGN-501
- Biological
- Lead sponsor
- UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Queen Creek, Arizona • Bakersfield, California • Murrieta, California + 12 more
- Conditions
- Cystitis, Interstitial, Painful Bladder Syndrome
- Interventions
- LiRIS®, LiRIS Placebo
- Combination Product
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 31
- States / cities
- Mobile, Alabama • Escondido, California • Los Angeles, California + 27 more
- Conditions
- Bladder Cancer
- Interventions
- induction cisplatin, induction 5-fluorouracil, induction gemcitabine, Induction BID radiation therapy, Induction QD radiation therapy, Consolidation BID radiation therapy, Consolidation QD radiation therapy, consolidation gemcitabine, consolidation 5-fluorouracil, consolidation cisplatin, radical cystectomy, Post-Induction Chemoradiotherapy Endoscopic Response Evaluation, adjuvant gemcitabine, adjuvant cisplatin
- Drug · Radiation · Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 10
- States / cities
- Atlanta, Georgia • Boise, Idaho • Springfield, Illinois + 5 more
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Interventions
- docetaxel, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 73
- States / cities
- Scottsdale, Arizona • Duarte, California • Palo Alto, California + 55 more
- Conditions
- Bladder Pain Syndrome, Interstitial Cystitis
- Interventions
- Hypnosis, Standard of Care
- Behavioral · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bladder Cancer
- Interventions
- Tremelimumab, Durvalumab, Bladder radiation, Intravesicular Therapy
- Drug · Radiation
- Lead sponsor
- Daniel George, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
- Interventions
- Autogene cevumeran, Atezolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Urinary Bladder Neoplasm, Neoplasm Metastasis
- Interventions
- Bempegaldesleukin, Nivolumab
- Biological
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- San Francisco, California • Whittier, California • Aurora, Colorado + 5 more
- Conditions
- Vesico-Ureteral Reflux
- Interventions
- OPTISON
- Drug
- Lead sponsor
- Kassa Darge
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Sclerosis, Urinary Bladder, Overactive
- Interventions
- WeB, Standard pelvic floor physical therapy
- Device · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Bladder Cancer
- Interventions
- Amrubicin
- Drug
- Lead sponsor
- Matthew Galsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Gilbert, Arizona • Indianapolis, Indiana • New York, New York
- Conditions
- Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Chronic Interstitial Cystitis
- Interventions
- AQX-1125 100 mg, AQX-1125 200 mg, Placebo
- Drug
- Lead sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 56
- States / cities
- Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 47 more
- Conditions
- Recurrent Bladder Carcinoma, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
- Interventions
- Cisplatin, Gemcitabine Hydrochloride, Sirolimus, Cystectomy
- Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Overactive Bladder Syndrome, Overactive Bladder, Urinary Frequency, Urinary Urgency
- Interventions
- BTL Emsella Chair, Sham BTL Emsella Chair
- Device
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Postoperative Urinary Tract Infection, Pelvic Organ Prolapse, Stress Urinary Incontinence
- Interventions
- gentamicin sulfate, Catheter clamping only
- Drug · Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- La Jolla, California • San Diego, California
- Conditions
- Urinary Retention, Neurogenic Bladder
- Interventions
- Self-management of urinary catheter
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- New York, New York • Rochester, New York
- Conditions
- Overactive Bladder
- Interventions
- Not listed
- Lead sponsor
- Michael Chancellor, MD
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Overactive Bladder, Urgency-frequency Syndrome, Urinary Frequency More Than Once at Night
- Interventions
- iStim TENS unit and Transvaginal Probe
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cancer
- Interventions
- entinostat
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland
- Conditions
- Superficial Bladder Cancer
- Interventions
- BC-819/PEI
- Biological
- Lead sponsor
- Anchiano Therapeutics Israel Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona